Ge Long Hui A P P·2025-10-16 10:26Core Viewpoint - Junshi Biosciences (688180.SH) announced that its product JS207, a recombinant humanized anti-PD-1 and VEGF bispecific antibody, has received FDA approval for a clinical trial application to compare its efficacy against Nivolumab in a Phase II/III study for patients with resectable, AGA-negative non-small cell lung cancer [1] Group 1 - JS207 is developed by the company and is primarily used for the treatment of advanced malignant tumors [1] - The drug can bind with high affinity to both PD-1 and VEGFA, effectively blocking the interaction between PD-1 and PD-L1/PD-L2, as well as inhibiting the binding of VEGF to its receptors [1] - JS207 exhibits characteristics of both immunotherapy and anti-angiogenic drugs, neutralizing VEGF to inhibit endothelial cell proliferation, improve the tumor microenvironment, and increase the infiltration of cytotoxic T lymphocytes in the tumor microenvironment, thereby achieving better anti-tumor activity [1]